Flag of the European Union EU Clinical Trials Register Help

Clinical trials for State of emergency

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    64 result(s) found for: State of emergency. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2016-003866-14 Sponsor Protocol Number: B5091007 Start Date*: 2017-06-15
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 3, Placebo-Controlled, Randomized, Observer-Blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older
    Medical condition: Primary C difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    20.0 10021881 - Infections and infestations 10012748 Diarrhoea, Clostridium difficile LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BG (Completed) SE (Completed) HU (Completed) BE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FI (Completed) PT (Completed) ES (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004762-15 Sponsor Protocol Number: VUMC38027 Start Date*: 2012-08-22
    Sponsor Name:VU Univeristy Medical Centre
    Full Title: Early pharmacological intervention to prevent delirium: HAlopeRidol PrOphylaxis in Older emergency department patieNts. The HARPOON study
    Medical condition: Delirium
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-003678-22 Sponsor Protocol Number: APHP220257 Start Date*: 2023-02-27
    Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (APHP)
    Full Title: Impact of the increase in post-filter ionized calcemia target on the efficacy of regional citrate anticoagulation during continuous renal replacement therapy in intensive care: multicenter randomiz...
    Medical condition: Adult patients hospitalized in intensive care with an indication of RRT with ARC during the stay.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000769-13 Sponsor Protocol Number: AP SEP 02-02 Start Date*: 2006-06-13
    Sponsor Name:AM-Pharma
    Full Title: A double-blind, randomized, placebo-controlled study to investigate the clinical efficacy and safety of two doses of Alkaline Phosphatase administered for three days in patients with severe sepsi...
    Medical condition: Severe sepsis and septic shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005578-24 Sponsor Protocol Number: OPT-OMA-ASTHMA Start Date*: 2022-03-10
    Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: Therapheutic optimization of omalizumab in allergic severe asthma patients by dose and frequency of administration adjustment
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003205-29 Sponsor Protocol Number: CAP2022-1 Start Date*: 2023-02-23
    Sponsor Name:Aphaia Pharma US LLC
    Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path...
    Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT)
    Disease: Version SOC Term Classification Code Term Level
    24.0 100000004861 10065542 Prediabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001255-40 Sponsor Protocol Number: STRIKE-SARS-CoV2 Start Date*: 2020-04-16
    Sponsor Name:Clínica Universidad de Navarra/Universidad de Navarra
    Full Title: Sarilumab Treatment In cytoKinE storm caused by infection with COVID-19.
    Medical condition: Severe pneumonia caused by infection with SARS CoV 2.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005768-74 Sponsor Protocol Number: ImmunoSep Start Date*: 2021-02-18
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: PERSONALIZED IMMUNOTHERAPY IN SEPSIS: A MULTICENTRE AND MULTINATIONAL, DOUBLE-BLIND, DOUBLE-DUMMY RANDOMIZED CLINICAL TRIAL (THE IMMUNOSEP TRIAL)
    Medical condition: Sepsis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10040053 Sepsis secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) NL (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002166-13 Sponsor Protocol Number: HUB-MdI-ICAT-COVID-201 Start Date*: 2020-07-09
    Sponsor Name:Dr. Ramón Lleonart Bellfill / Dr. Xavier Corbella Virós
    Full Title: Randomized, open, multicenter phase II clinical trial, proof of concept, to evaluate efficacy and safety of Icatibant in hospitalized patients with SARS-COV-2 (COVID-19) without assisted ventilatio...
    Medical condition: Pneumonia caused by COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    20.0 10022891 - Investigations 10070255 Coronavirus test positive PT
    23.0 10021881 - Infections and infestations 10084381 Coronavirus pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Completed) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-002403-13 Sponsor Protocol Number: Ularitide-1502 Start Date*: 2006-11-20
    Sponsor Name:PDL BioPharma Inc
    Full Title: A Phase 3, Randomized, Double-blinded, Placebo-controlled Study of Ularitide in the Treatment of Subjects with Acute Decompensated Heart Failure
    Medical condition: Acute decompensated heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) LT (Prematurely Ended) AT (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2019-000245-12 Sponsor Protocol Number: Repha_1436 Start Date*: 2020-01-20
    Sponsor Name:Repha GmbH
    Full Title: Controlled clinical trial to evaluate the efficacy and safety of MYRRHINIL-INTEST® versus placebo in patients with diarrhea-dominant irritable bowel syndrome (IBS-D) and patients with mixed-type ir...
    Medical condition: A confirmed diagnosis of irritable bowel syndrome (IBS-D or IBS-M) by a specialist in gastroenterology and/or internal medicine and/or general medicine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10023002 Irritable bowel LLT
    26.0 10017947 - Gastrointestinal disorders 10060845 Diarrhea predominant irritable bowel syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2023-000102-25 Sponsor Protocol Number: PRECISION Start Date*: 2023-05-30
    Sponsor Name:Hellenic Institute for the Study of Sepsis
    Full Title: SAFETY AND EFFICACY OF ANAKINRA TREATMENT FOR PATIENTS WITH PERSISENT RESPIRATORY SYMPTOMS POST ACUTE COVID AND IMMUNE SYSTEM ACTIVATION: THE PRECISION DOUBLE-BLIND, RANDOMIZED CLINICAL TRIAL
    Medical condition: Post-acute COVID-19 syndrome (PACS)
    Disease: Version SOC Term Classification Code Term Level
    24.1 100000004862 10085504 Long COVID LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001477-33 Sponsor Protocol Number: 071102 Start Date*: 2016-12-01
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleed...
    Medical condition: Hereditary severe von Willebrand Disease in children
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) IT (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) CZ (Completed) ES (Trial now transitioned) FR (Trial now transitioned) DE (Completed) NL (Completed) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2019-003350-80 Sponsor Protocol Number: APHP190843 Start Date*: 2020-01-15
    Sponsor Name:Université de Sherbrooke
    Full Title: Lessening Organ Dysfunction with VITamin C (LOVIT)
    Medical condition: Sepsis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004266-35 Sponsor Protocol Number: MAICOVID-19 Start Date*: 2021-12-22
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA DI MODENA
    Full Title: A phase 3, multicentre, single-blinded, randomized controlled study to compare the efficacy and safety of Casirivimab and Imdevimab or Bamlanivimab and Etesevimab or Sotrovimab in COVID-19 home pat...
    Medical condition: Mild to moderate COVID-19 patients at high risk of progression to severe COVID-19 and / or hospitalization
    Disease: Version SOC Term Classification Code Term Level
    23.1 10042613 - Surgical and medical procedures 10084460 COVID-19 treatment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002767-30 Sponsor Protocol Number: ACT17453 Start Date*: 2023-02-23
    Sponsor Name:Sanofi-aventis recherche & developpement
    Full Title: A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory ...
    Medical condition: Relapsed/refractory multiple myeloma (RRMM)
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004864 10086466 Relapsed/refractory multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004449-35 Sponsor Protocol Number: 80-86600-98-19047 Start Date*: 2021-05-06
    Sponsor Name:ZonMw
    Full Title: Antibiotic treatment following surgical drainage of perianal abscess: a double-blind, placebo-controlled, randomized trial
    Medical condition: Perianal fistula
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000620-18 Sponsor Protocol Number: RC20_0082 Start Date*: 2021-02-19
    Sponsor Name:Nantes University Hospital
    Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the...
    Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004177-83 Sponsor Protocol Number: 37202 Start Date*: 2011-11-14
    Sponsor Name:Academic Medical Center
    Full Title: Boosting the oxytocin system in acute trauma: The effectiveness of intranasal oxytocin treatments and stimulation of social support on preventing trauma related psychopathology
    Medical condition: Posttraumatic Stress Disorder (PTSD) according to criteria in the DSM-IV
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10036316 Post-traumatic stress disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:27:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA